港股異動 | 康希諾生物-B(6185.HK)逆勢漲4.6% 旗下鼻噴霧式/吸入型新冠疫苗正在申請緊急使用
格隆匯6月4日丨康希諾生物-B(6185.HK)逆勢漲4.6%,報332港元;康希諾(688185.SH)亦漲逾4%。中國工程院院士陳薇在昨日舉行的浦江論壇上表示,疫苗既可以通過皮下注射,還可以通過鼻噴霧式吸入,後者所需的劑量是前者的1/5,而且可以形成黏膜免疫。“鼻噴霧式/吸入型新冠疫苗正在申請緊急使用。”6月2日,康希諾董事長兼CEO宇學峯在青島的一次會議上表示,康希諾的鼻噴霧式/吸入型新冠疫苗現已進入二期臨牀試驗。另據港交所披露文件,5月31日,摩根大通在康希諾生物(06185.HK)的持股比例從5.92%上升至9.25%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.